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ABSTRACT 
    In this study, cyclic arginine-glycine-aspartic acid (RGD) peptide-modified 
amine-terminated generation 5 poly(amidoamine) (G5.NH2 PAMAM) dendrimers 
were prepared for the encapsulation of the anticancer drug doxorubicin (DOX) for 
targeted delivery to cancer cells overexpressing αvβ3 integrin cell surface receptors. 
First, the thiolated RGD peptide was linked to polyethylene glycol (PEG) via the 
bifunctional cross-linking reagent 6-maleimidohexanoic acid N-hydroxysuccinimide 
ester (MHS). Then a dendrimer modification process was performed in which the 
PEGylated RGD peptide and fluorescein isothiocyanate (FI) were covalently attached 
to the G5 dendrimers.  This process was finally followed by acetylation of the 
remaining dendrimer terminal amines. The experimental results show that each 
G5.NHAc-FI-PEG-RGD dendrimer approximately encapsulated six DOX molecules. 
This formed complex is water soluble and stable. In vitro release studies proved that 
the multifunctional dendrimers facilitate a sustained release of DOX. More interesting, 
one-dimensional NMR and two-dimensional NMR were applied to investigate the 
interactions between dendrimers and DOX. Here, the impact of the environmental pH 
on the release rate of DOX from G5.NHAc-FI-PEG-RGD/DOX was fully studied. 
Furthermore, cell biological studies demonstrated that G5.NHAc-FI-PEG-RGD 
dendrimers have no cytotoxicity towards U87-MG cancer cells but that 
G5.NHAc-FI-PEG-RGD/DOX complexes have almost the same cytotoxicity as DOX 
alone. Moreover, due to the targeting ability of RGD, this dendrimer/drug system can 
also specifically target and display therapeutic efficacy to cancer cells overexpressing αvβ3 integrins. The cellular internalization of the multifunctionalized dendrimer was 
shown to be receptor mediated to an important extent. According to this study, we can 
say that G5.NHAc-FI-PEG-RGD is a promising system for the targeted therapy of 
different types of cancer. 
Keywords: dendrimers; RGD peptide; doxorubicin; targeted cancer therapy.
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RESUMO 
Neste trabalho, foram preparados dendrímeros de poli(amidoamina) (PAMAM) 
de geração 5 (G5) funcionalizados com o péptido cíclico RGD para o encapsulamento 
do fármaco anticancerígeno doxorubicina (DOX) e sua entrega em células 
cancerígenas que expressem elevadas quantidades de integrinas αvβ3 na sua superfície 
(entrega específica do fármaco em células-alvo). No processo de síntese, o péptido 
contendo um grupo tiol foi primeiro ligado a uma cadeia de polietilenoglicol (PEG) 
através de um reagente de reticulação bi-funcional. De seguida, os dendrímeros foram 
ligados covalentemente ao péptido PEGilado e, ainda, ao isotiocianato de fluoresceína 
(FI), seguindo-se a acetilação (Ac) das aminas terminais remanescentes no 
dendrímero para se obter o sistema final G5.NHAc-FI-PEG-RGD. Os resultados 
experimentais mostram que, aproximadamente, existem 6 moléculas de DOX 
encapsuladas por  G5.NHAc-FI-PEG-RGD, sendo estes complexos solúveis e 
estáveis em água. Os estudos in vitro mostraram que a libertação do fármaco a partir 
dos dendrímeros multifuncionalizados é controlada. O trabalho envolveu, ainda, 
estudos de NMR mono- e bi-dimensional na investigação da interacção existente entre 
os dendrímeros e as moléculas de DOX, e ainda a avaliação do impacto do pH 
ambiental na velocidade de libertação da DOX. Realizaram-se, igualmente, estudos 
biológicos com células U87-MG, os quais mostraram que os sistemas 
G5.NHAc-FI-PEG-RGD não apresentavam toxicidade e que, quando complexados 
com a DOX, apresentavam uma citotoxicidade semelhante à do fármaco usado de 
forma isolada.  
Dada a afinidade do péptido RGD para as integrinas presentes em grande 
quantidade à superfície das células U87-MG, o sistema G5.NHAc-FI-PEG-RGD 
mostrou-se muito eficaz na entrega específica do fármaco e consequente eficácia 
terapêutica. A entrega do fármaco nas células mostrou ser, numa importante extensão, 
mediada pelos receptores (integrinas αvβ3) presentes à sua superfície. Este trabalho 
mostrou que os dendrímeros multifuncionalizados G5.NHAc-FI-PEG-RGD são 
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bastante promissores como sistemas para a entrega específica de fármacos em células 
cancerígenas. 
 
Palavras chave: dendrímeros; péptidos RGD; doxorubicina; terapia do cancro 
dirigida 
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CHAPTER 1 – INTRODUCTION 
 
1.1 Nanotechnology as a solution for drug delivery 
 
In the last few years, the application of nanoparticles (NPs) in various disciplines 
and particularly in healthcare has been increasingly common, including but not 
limited to therapeutics (drug and gene delivery), diagnostics, and imaging (1-4). 
Among all of these applications, NPs as drug delivery vehicles are opening new 
opportunities for conventional drug formulations that present poor bioavailability or 
drug instability. The main advantages of using NPs as drug delivery systems are that 
they cannot only facilitate a controlled release of the drug (5) but also accumulate at 
the target sites, reducing the unwanted side effects of the therapeutic agents (6). There 
are several kinds of NPs that can serve as carriers for controlled drug delivery, such as 
ceramic NPs, metallic NPs, and polymer and dendrimer-based NPs (7-10). 
 
1.2 Introduction of dendrimer 
 
    Dendrimers are polymeric molecules where the monomers are organized in 
branches that emanate radially from a central core (Figure 1) (11). The size of 
dendrimers is sufficiently small (e.g., the diameter of a generation 5 (G5) 
poly(amidoamine) (PAMAM) dendrimer is 5.4 nm (12)), which enables them to pass 
through the renal filter (13), eliminating the need for these molecules to be 
biodegradable. On the other hand, the surface of dendrimers can be easily modified 
with numerous functionalities, making them well suited as nano-scaffolds with 
desired targeting, imaging and therapeutic functions (14-16). Furthermore, the 
internal cavities of dendrimers can be used for host-guest interactions and 
encapsulation of guest molecules (1, 17-20). In addition, the terminal groups of 
dendrimers can also be modulated to avoid issues of toxicity and nonspecific cell 
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membrane binding. For example, acetylation (21-24), hydroxylation (25) or 
carboxylation (26) of dendrimers possessing amine termini can significantly improve 
the biocompatibility of dendrimers. Polyethylene glycol (PEG), which behaves as a 
linker and which is considered as the gold standard for stealth polymers in the 
emerging field of polymer-based drug delivery, may also be considered when 
modifying dendrimers. In fact, full or partial PEGylation of dendrimers effectively 
increases the blood stream circulation time of these molecules as well as increases 
their biocompatibility (27-29).  
 
 
 
Figure 1 – 2D schematic illustration of a dendrimer. Taken from ref. (30) . 
 
The synthesis used for dendrimer preparation permits an almost entire control 
over critical molecular design parameters such as size, shape, surface/interior 
chemistry, flexibility, and topology. As is shown in Figure 2, in principle, there are 
two ways for the synthesis of dendrimers. “A divergent method”, in which the 
synthesis begins from a polyfunctional core and continues radially outwards by 
successive stepwise activation and condensation. Dendrimers can also be prepared 
using a convergent method, where preformed branched dendritic polymers connect to 
each other via a central core-mediated reaction (31). 
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Figure 2 – Two principle synthetic methods for constructing dendritic 
macromolecules (dendrons): (a) the divergent method and (b) the convergent method. 
Taken from ref. (31).  
     
Among all the dendrimers, the most commonly referenced dendrimers used in 
nanomedicine are based on PAMAM (Figure 3), poly(L-lysine) (PLL), polyesters, 
polypropyleneimine (PPI) and poly(2,2-bis (hydroxymethyl) propionic acid) (30). In 
conclusion, the well-defined structure, compact globular shape, mono-dispersed size, 
and controllable surface functionalities of dendrimers make them versatile platforms 
for drug delivery applications. 
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Figure 3 – Structure of a PAMAM dendrimer (StarburstTM). 
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1.3 Dendrimer – based drug delivery systems 
 
Doxorubicin (DOX) (structure see Figure 30) is a cancer drug widely used in the 
treatment of hematological malignancies, many types of carcinoma, and soft tissue 
sarcomas (32-34). Similar to other conventional anticancer drugs, free DOX is 
water-insoluble, cytotoxic to normal cells or tissues and easy to be cleared by the 
blood stream (20), limiting its clinical applications. As a consequence, it may be 
advantageous to use dendrimers as carriers for free DOX (35).  
DOX can be loaded on dendrimers either through physical 
encapsulation/complexation or covalent linkage (Figure 4) (20, 36). Both of these two 
methods have their own advantages and drawbacks. 
 
 
 
Figure 4 – Dendrimer drug delivery systems of different types (the blue color 
represents the drug agents). Drugs can be physically entrapped inside the dendrimer 
(a), adsorbed on the surface of the dendrimer through intermolecular interaction 
forces (b), or be conjugated to the dendrimer (c). Taken from ref. (37). 
 
1.3.1 DENDRIMER/DRUG COMPLEXES 
     
    Both hydrophobic and hydrophilic drugs can be carried by dendrimers. The 
hydrophobic drugs can be easily encapsulated inside the hydrophobic internal 
“cavities” of an appropriately designed dendrimer (18). For hydrophilic drugs, they 
can be complexed with the dendrimer surface groups through hydrogen bonding, van 
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der Waals interactions, and electrostatic interactions (38). Sustained release of 
encapsulated molecules can be achieved on the basis of the size, shape and surface 
charge of the dendrimer and even through finely tuned hydrolytic conditions for 
partial or complete removal of the dendrimer shell (37, 39).     
In comparison with a dendrimer/drug conjugate, the formation of a 
dendrimer/drug complex is much more simple and straightforward, and is normally 
done by just mixing the dendrimers and the drugs in either an aqueous solution or in a 
mixture of solvents. The chemical structure of the drug to be loaded remains 
unchanged after the complexation process, which ensures the therapeutic efficacy of 
the drug. However, it is usually difficult to control the loading capacity and the 
release profile of the drugs because the loading of the drug is based on physical 
interactions between the drug and the dendrimer. In the study of Wang et al. (1, 20), 
they modified acetylated G5 PAMAM dendrimer with fluorescein isothiocyanate (FI) 
and folic acid (FA), then used this modified dendrimer to encapsulate drugs. They 
found that approximately one DOX molecule could be encapsulated within each 
G5.NHAc-FI-FA dendrimer, and that 3.7 molecules of 2-methoxyestradiol could be 
encapsulated into each G5.NHAc-FI-FA using the same molar ratio of dendrimers 
and drugs. They hypothesized that the higher encapsulation efficiency of 
2-methoxyestadiol compared to that of DOX might be due to the smaller molecular 
size of 2-methoxyestadiol (Mw = 302.4 g/mol) relative to that of DOX (Mw = 543.5 
g/mol). The small size of 2-methoxyestadiol in the dendrimer-based scaffold thus 
accounts for a higher encapsulation efficiency; in contrast, the larger size of DOX in 
the dendrimer-base scaffold will limit its entrance and retention within the dendrimer 
interior. 
 
1.3.2 DENDRIMER/DRUG CONJUGATES 	  
Dendrimer/drug conjugates are obtained when the chemotherapeutic drugs are 
covalently attached to the peripheral groups of the dendrimer. Conjugation generally 
requires multi-step organic reactions, leading to a low yield of the final conjugate. 
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Also, in most of the cases, the covalent conjugation chemistry has to be optimized in 
order to get cleavable bonds and allow the release of the drug molecules under 
specific biological conditions. However, there is an extremely useful advantage of 
dendrimer/drug conjugates related with the fact that the covalent linkage between 
dendrimers and drugs is stable in vivo, providing a better control over drug release. 
Until now, numerous chemotherapeutic drugs have been conjugated onto the surface 
of dendrimers through amide, ester, hydrazone, imine, disulfide, carbamate, and 
enzyme-cleavable peptide sequence bonds (35, 40-42). Each linkage system has its 
own cleavage mechanism to separate the drug molecules from the dendrimers such as 
reactions promoted by endogenous physiological factors like the redox potential, pH, 
and the presence of hydrolytic enzymes (Figure 5) (41, 43). In a recent study, Choi et 
al. (44) reported the light-controlled release of caged DOX from folate receptor 
(FR)-targeting PAMAM dendrimer nanoconjugates. They attached DOX through a 
photocleavable linkage to a FA-attached G5 PAMAM dendrimer. In vitro studies 
showed that the drug release from this conjugate was controllable, and highly 
dependent on UV light exposure time.  
 
 
 
Figure 5 – Different mechanisms for stimuli-responsive release of active agents from 
nanocarriers: (a) supramolecular complexes like dendritic core-shell particles with a 
cleavable shell and (b) dendritic scaffolds with attached solubilizing/stealth groups 
using cleavable linkers for the drug conjugation. Adapted from ref. (42). 
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1.4 Targeted drug delivery 
 
Several drugs have been discovered that exhibit anticancer properties. 
Unfortunately, most of them have undesirable toxicity towards normal tissues, i.e., 
they do not target only cancer cells, or they do not interfere only with the metabolic 
pathways of cancer cells. Nowadays, researchers have begun to focus on decreasing 
the side effects associated with drugs, as well as discovering drugs with improved 
delivery ability to tumor tissue in man. This goal should lead to an improved quality 
of life and an increased life expectancy for the patients.  
There are several methods that have been studied to direct drugs to the target 
tumors. In general, two different approaches can be used: passive and active. The 
action mechanism of passive targeting drug delivery systems is based on the 
anatomical characteristics of the tumor tissue and is referred to as the “enhanced 
permeability and retention” (EPR) effect. In this phenomenon, there is an 
accumulation of the delivery systems that transport the drug into the tumor (solid 
tumor) as a consequence of an increased permeability of the immature blood vessels 
that were formed in the tumor interior and the absence of lymphatic drainage (45). 
With EPR targeting, drugs are released locally and taken up by tumor cells 
subsequently. In contrast, active targeting can be achieved using specific interactions 
between receptors on the cell surface and exposed targeting moieties in the drug 
delivery system (46). In this approach, a vehicle can be used to carry a therapeutic or 
a bioactive agent such that this agent directly binds to the target site for selective 
delivery. Therefore, the active approach takes advantage of the EPR effect but further 
increases selectivity through receptor-mediated uptake by target cancer cells. In this 
case, to further improve their efficiency, drug carriers can be modified with different 
types of targeting agents (47). For example, the literature reports the functionalization 
of dendrimers with FA (46), hyaluronic acid (HA) (48), monoclonal antibodies (49), 
and  peptides (50, 51) before drug loading. 
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1.4.1 FA TARGETED DELIVERY SYSTEMS 
 
The FR is a glycosylphosphatidylinositol (GPI)-linked membrane glycoprotein 
that has folate affinity, normally with an apparent molecular weight of 38–40 kDa 
(52). It is reported that FR is expressed or overexpressed in many types of tumors, 
including ovarian (52 of 56 cases tested), endometrial (10 of 11 cases tested), 
colorectal (6 of 27 cases tested), breast (11 of 53 cases tested), lung (6 of 18 cases 
tested) and kidney (9 of 18 cases tested) tumors, as well as brain metastases derived 
from epithelial cancers (4 of 5 cases tested) and neuroendocrine carcinomas (3 of 21 
cases tested) (53). However, the receptor is generally absent in most healthy tissues 
with the exceptions of the choroid plexus and the placenta, and low receptor levels are 
detected in the lung, thyroid and kidney (54). The general model for the cellular 
uptake of drug conjugates or complexes targeted to the FR is illustrated in Figure 6. 
The high concentration of FR on the surface of tumor cells makes it a good agent for 
targeted drug delivery to the mentioned tumors. In this respect, Hong et al. (55) have 
demonstrated that 5-6 FA per G5 PAMAM dendrimer achieved saturated binding 
affinity. 
 
 
 
Figure 6 – A schematic diagram of the FR-mediated endocytosis pathway. Adapted 
from ref. (56). 
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    The FA-mediated targeting enables both dendrimer/drug conjugates and 
dendrimer/drug complexes to specifically inhibit the growth of tumor cells. A study of 
Patri et al. (46) used G5 PAMAM dendrimers as a platform to covalently link FA 
(G5-FA), followed by complexation or conjugation with the anticancer drug 
methotrexate (MTX). In in vitro biological experiments using the same concentration 
of MTX, cell viability was much lower when the system G5-FA/MTX was applied to 
KB cells overexpressing the FA receptor (FAR positive cells, FAR+) (Figure 7) when 
compared to KB cells with FA pre-blocked FAR (Figure 8). Moreover, the results 
also showed that a cleavable, covalently linked dendrimer conjugate performed better 
targeting drug delivery, as it does not release the drug prematurely in biological 
conditions (Figure 9). 
 
 
 
Figure 7 – Cytotoxicity of covalent conjugates with MTX and dendrimer inclusion 
complexes with MTX tested on KB cells over-expressing the FA receptor (FAR+). 
Cells were pre-incubated for 1.5 h with MTX containing dendrimers, and dendrimers 
without drug, washed with medium and further incubated for 72 h. Adapted from ref. 
(46).  
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Figure 8 – Specificity of delivering FA-targeted MTX conjugates and inclusion 
complexes. Cytotoxicity was tested using KB (FAR+) cells after initial blocking with 
cell culture with free FA (9 µM) followed by pre-incubation with compounds for 1.5 
h, wash and further incubation for 72 h. Adapted from ref. (46). 
 
 
Figure 9 – Comparative release profile of MTX from inclusion complexes and 
conjugates in water and phosphate-buffered saline (PBS). Adapted from ref. (46) 
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1.4.2 HYALURONIC ACID TARGETED DELIVERY SYSTEMS 
 
Hyaluronic acid (HA) is a linear polysaccharide of alternating D-glucuronic acid 
(GlcUA) and N-acetyl-D-glucosamine (GlcNAc) units (see Figure 10). It is the only 
non-sulfated glycosaminoglycan and it occurs primarily in vivo as sodium hyaluronate. 
HA can be found present in the extracellular matrix (e.g., in cartilage), and in the 
synovial fluid of joints. It is an immunoneutral building block that can be used for 
preparing biocompatible and biodegradable biomaterials, and has been employed as 
both a vehicle and an angiostatic agent in cancer therapy (57).  
 
Figure 10 – Structure of HA. Adapted from ref. (47). 
 
HA serves a variety of functions within the extracellular matrix. One of its most 
important functions is that it can direct receptor-mediated effects on cells. These 
effects occur through the activation of intracellular signaling pathways inside cells. 
Numerous cell-membrane-localized receptors (HA binding proteins) have been 
identified, such as CD44, RHAMM, IVd4, and the liver endothelial cell clearance 
receptor (58-60), among which the CD44 receptors on tumor surfaces have been well 
studied. Moreover, HA acts as a signaling molecule in cell motility, inflammation, 
wound healing, and cancer metastasis (61).  
The targeting principle of HA is that most malignant solid tumors contain 
elevated levels of HA compared to healthy cells. Because of poor differentiation and a 
lower survival rate of some human carcinomas, the level of HA in malignant solid 
tumors becomes higher, providing a matrix that facilitates invasion. In general, HA 
internalization is matrix receptor mediated. Receptors including CD44, can mediate 
cell-matrix interactions, giving information to the cells but also giving feedback to the 
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matrix (57).	  So HA is a promising targeting agent that we can use to conjugate to the 
drug carrier system. Low molecular weight HA has been reported to be directly 
conjugated to cancer drugs such as butyric acid (62), paclitaxel (63), and DOX (64). 
These studies proved that HA bearing polymers can be a suitable non-toxic drug 
carrier. These polymer/drug systems can be quickly internalized into cancer cells, and 
release the drug in a sustained manner restoring the original cytotoxicity of drugs. 	  
    The advantages of HA as a targeting agent are not limited to the above 
description. HA production is quite biocompatible, which to a large extent facilitates 
the synthesis and design of HA and drug bearing bioconjugates. Moreover, HA is 
hydrophilic, which allows its manipulation and application in aqueous media.  
However, a possible disadvantage of HA is the lack of accurate structural 
characterization of the conjugates (47). 
 
1.4.3 MONOCLONAL ANTIBODY TARGETED DELIVERY SYSTEMS 
 
As we can see in Figure 11, the general structure of antibodies (150kDa) consist 
of two heavy chains (50kDa each) and two light chains (25kDa each) that are linked 
by disulfide bonds (47). The principle of antibody – targeted delivery systems is that 
there are specific antigens overexpressed or expressed on the surface of cancer cells, 
and so selective antibodies can be conjugated with cytotoxic drugs or drug delivery 
systems (65, 66).  These conjugates can be internalized via receptor – mediated 
endocytosis and then active drugs can be released into the target sites without a 
decrease in their original activity.  The use of antibodies as targeting agents has a 
long story. In 2000, the Food and Drug Administration (FDA) approved Mylotarg® 
(gemtuzumab-ozogamicin) to be utilized in the clinic as an antibody-drug 
immunoconjugate for the treatment of acute myelogenous leukemia (AML) (67).  
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Figure 11 – Structure of an antibody. Adapted from ref. (47). 
 
    According to the different kinds of antigens overexpressed on tumor cell surfaces, 
there are different kinds of drugs that can be used in the immunoconjugates, such as 
calicheamicin (67), maytansine derivative DM1 (68), CC-1065 (69), 
monomethylauristatin E (MMAE) (70), DOX (71) and a second-generation taxoid 
(65). In addition, there are also different sorts of linker moieties between antibodies 
and drugs that can be chosen, including the hydrazine (72), peptide (73), and disulfide 
(65) linkers. In order to achieve the highest efficacy of the immunoconjugates, it is 
critically important to choose a linker that is stable when in circulation in the body 
and that can be efficiently cleaved inside the cancer cells. The three mentioned linkers 
are the most common and have their own advantages and disadvantages. For instance, 
the hydrazone linker is good to use under acidic conditions in lysosomes (about pH 5) 
to release the cytotoxic drug via non-enzymatic hydrolysis, but it is unstable during 
circulation. Peptide linkers are specifically designed for rapid lysosomal hydrolysis. 
Disulfide linkers can be easily cleaved inside the tumor cells via disulfide exchange 
(reduction reaction) (47). 
    However, it is important to take into consideration the molecular weight of the 
antibody-drug conjugates, since a high molecular weight is good in terms of the EPR 
effect, but a big size often leads to poor penetration into tumor cells. Researchers 
found some methods to truncate antibody fragments in order to achieve a faster 
penetration into tumors, but unfortunately, the circulation time was shortened by renal 
clearance (74). Another problem related with the antibody containing drug delivery 
systems is that there is a limited number of molecules that can be loaded without 
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decreasing the binding affinity of the antibody targeting moiety (66).  
 
1.4.4 GLYCOSYLATED DENDRIMER-BASED TARGETED DELIVERY 
SYSTEMS 
 
The term ‘glycodendrimer’ has been used to describe a wide range of dendrimer 
architectures that incorporate carbohydrates into their structure. It is well known that 
asialoglycoprotein receptors (ASGPR) are present on the surface of hepatocytes and 
several human carcinoma cell lines with a high density, showing a strong binding 
affinity with galactose. Therefore, dendrimers have been glycoconjugated for 
targeting human liver cancer cells overexpressing the ASGPR (75). In general, there 
are three kinds of glycodendrimers: carbohydrate coated, carbohydrate-centered and 
carbohydrate-based types. Bhadra et al. (76) reported the use of galactose-coated PPI 
dendrimers for targeted delivery of the antimalarial drug primaquine phosphate (PP) 
to the liver. The results revealed that galactose coating of PPI dendrimers has higher 
drug entrapment efficiency, longer drug release time and higher hepatic accumulation 
of PP compared with non-functionalized PPI dendrimer formulations. 
 
1.4.5 PEPTIDE TARGETED DELIVERY SYSTEMS 
 
There are several tumor-associated receptors for peptides. Nowadays, peptide 
targeted delivery systems are becoming more and more attractive because the needed 
sequences of amino acids can be determined by screening of combinatorial libraries 
and can be easily artificially synthesized. This is a huge advantage for most 
gastrointestinal cancers, which are difficult to treat due to their multidrug-resistance 
(47). Fortunately, several peptides have been found that have effective targeting 
ability, such as the arginine-glycine-aspartic acid (RGD) peptide (77), bombesin 
(BBN) (78) and gastrin-releasing peptide (GRP, a bombesin-like peptide) (79).  
The RGD peptide has a binding high affinity to αvβ3 integrin receptors 
overexpressed on the surface of certain tumor cells (80) and of endothelial cells lining 
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the newly formed blood capillaries inside solid tumors (81). Different RGD peptides 
can be used as targeting delivery systems, such as c(RGDyK), c(RGDfK), 
[c(RGDyK)2], RGD4C, and RGD10 (Figure 12) (80). Numerous studies used RGD 
modified PAMAM dendrimers to target tumor cells and tumor microvasculature 
(82-84). For instance, Shukla et al. (82) developed a G5 PAMAM 
dendrimer–RGD-4C peptide conjugate and studied its in vitro targeting efficacy to 
integrin receptor expressing cells. Similarly, Saijie et al. (83)  covalently linked 
DOX to RGD-modified PAMAM dendrimer conjugates (an acid-sensitive cis 
-aconityl linkage was used to link DOX to the surface of the dendrimer). Their results 
demonstrated that RGD modified dendrimers significantly improved the therapeutic 
effect against murine B16 melanoma compared with the same dendrimer without 
RGD modification. Cyclic RGDs have also been attached to DOTA-conjugated mono, 
di-, and tetravalent dendrimeric alkynes for αvβ3 integrin targeting (51). The binding 
characteristics of these systems were evaluated in vitro and in vivo using human 
SK-RC-52 cells and the mice-bearing xenografted SK-RC-52 tumor model. It was 
shown through biodistribution studies that the tetrameric RGD-dendrimer showed the 
highest level of tumor targeting. These studies demonstrated that RGD-modified 
dendrimers could be used as a platform for therapy and imaging of tumor tissues 
overexpressing αvβ3 integrins. 
There are obvious advantages of peptide targeting delivery systems. However, 
the inherent problem of these systems is that the stability of peptides in circulation is 
difficult to control. So it is important to make an appropriate design of these delivery 
systems to prevent or slow down the amide hydrolysis (47). 
In general, the research involving dendrimers and targeted delivery has evolved 
well. However, more efforts are needed to develop a system that is effective and that 
is of low cost.  
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Figure 12 – Chemical structures of c(RGDyK), c(RGDfK), [c(RGDyK)2], RGD4C, 
and RGD10. Adapted from ref. (80).  
 
1.5 Host-Guest interactions 
     
   To better understand the influence of dendrimer terminal groups on the properties 
of dendrimer-based drug delivery systems, the interaction between drug molecules 
and dendrimers has been investigated via various techniques, such as 
Ultraviolet-visible (UV−vis) spectroscopy (20) ，  high performance liquid 
chromatography (HPLC) (16) and NMR (85).	   Among all these methods, NMR 
techniques, including 1H and 13C NMR titrations, two-dimensional nuclear 
Overhauser enhancement spectroscopy (2D-NOESY), and diffusion-ordered 
spectroscopy (DOSY), have been demonstrated to be effective in studying the 
dendrimer host−drug guest interactions. Zhang et al. encapsulated DOX within 
G5.NHAc, G5.NGlyOH, and G5.SAH dendrimers (86). 1H NMR, 2D-NOESY, and 
DOSY techniques were used to investigate the host-guest interactions of these 
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dendrimer/DOX complexes. The results showed that DOX was successfully 
incorporated into dendrimers although the exchange rate between free and 
coordinated DOX was high. Moreover, calculations based on DOSY experiments 
showed the diffusion coefficients of DOX, and proved that the interaction intensity 
between dendrimer and DOX follows the order of G5.NHAc/DOX > 
G5.NGlyOH/DOX > G5.SAH/DOX.  
 
1.6 Objectives & General Strategy of the Thesis 
 
The objective of the present study was to prepare RGD peptide-modified G5 
PAMAM dendrimers for the encapsulation of the anticancer drug DOX for targeted 
delivery to cancer cells overexpressing the αVβ3 integrin. As shown in Figure 13, in 
the synthesis process, the thiolated RGD peptide was first linked to PEG (PEG in the 
form of NH2-PEG-COOH) making use of MHS. The formed PEGylated RGD peptide 
with carboxyl end groups was covalently attached onto the G5 PAMAM dendrimers 
via 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) coupling 
chemistry. After linking FI and acetylation of the remaining dendrimer terminal 
amines, multifunctional FI- and RGD- modified G5 PAMAM dendrimers were 
formed. These multifunctional dendrimers were used to encapsulate DOX. The 
interactions between the drug molecules and the modified dendrimers were then 
investigated using NMR techniques, including 1H NMR, 2D-NOESY, and DOSY. 
The release kinetics of DOX was also investigated. Finally, the targeting and 
therapeutic capabilities of these nanomaterials were investigated in vitro using 
U87-MG cells that overexpress the αVβ3 integrin. 
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Figure 13 – Synthesis procedure of G5.NHAc-FI-PEG-RGD/DOX.
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                          CHAPTER 2 – MATERIALS AND METHODS 
 
2.1 Materials and reagents 
    G5 PAMAM dendrimers possessing ethylenediamine cores and amine termini 
(PAMAM G5.NH2) were purchased in methanol solution from Dendritech Inc.. 
Acetic anhydride (purity > 98%) was purchased from Panreac. Triethylamine (TEA) 
(purity > 99%) was purchased from MERCK. PEG having on one end an amine group 
and on the other end a carboxyl group (NH2-PEG-COOH, M.W. = 2000 g/mol) was 
purchased from Yarebio (China). A cyclic RGD peptide with molecular weight of 
706.8 g/mol was purchased from GenicBio (Shanghai, China). All other chemicals 
were obtained from SIGMA-ALDRICH unless otherwise stated and used as received. 
Cell culture dishes were from Nunc. The dialysis membranes were from Spectrum® 
labs and the filters used for solution sterilization were from VWR™ with a pore size of 
0.22µm. U87-MG cells were from European Collection of Cell Cultures (ECACC) 
(Salisbury, UK). 
 
2.2 Synthesis of G5.NHAc-FI-PEG-RGD dendrimers 
 
HOOC-PEG-RGD was synthesized by the following method. NH2-PEG-COOH 
(63 mg, 0.03 mmol) was dissolved in 3 mL dimethyl sulfoxide (DMSO), then MHS 
(9.25 mg, 0.03 mmol) in DMSO (3 mL) was added into the NH2-PEG-COOH 
solution under vigorous magnetic stirring at room temperature for 8 h. Afterwards, 
RGD (21.2 mg, 0.03 mmol) in DMSO (4 mL) was added into the solution at room 
temperature for 24 h. The reaction mixture was dialyzed against distilled water (3 
times, 3 L) through a 1,000 MWCO membrane for 24 h, followed by lyophilization. 
    To conjugate FI and PEG-RGD to G5 PAMAM dendrimer, PAMAM G5.NH2 
dendrimers (57.7 mg, 0.002 mmol) in methanol solution were dissolved in 5 mL of 
PBS 0.1 M (pH 7.4). FI (11.68 mg, 0.03 mmol) was dissolved in DMSO (5 mL) and 
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added dropwise into the dendrimer PBS buffer solution at room temperature and 
stirred vigorously for 12 hours. The reaction mixture was first dialyzed against PBS 
buffer and later against distilled water through a 12,000 MWCO membrane for 2 days 
to remove any excess of free FI. This was followed by lyophilization to get the 
G5.NH2-FI dendrimers. The RGD-PEG-COOH (20 mg, 0.0087 mmol) was then 
reacted with 14-fold excess of EDC in DMSO for two hours to activate the –COOH 
functional groups. This solution was then added dropwise to the aqueous solution of 
the G5.NH2-FI dendrimer (19.56 mg, 0.00058 mmol) and reacted for two days. The 
same dialysis and lyphophilization steps were done in order to achieve pure 
G5.NH-FI-PEG-RGD.  
The final synthesis step of the multifunctional dendrimer was to neutralize the 
remaining amine groups of the G5.NH2-FI-PEG-RGD dendrimers. First, the 
G5.NH2-FI-PEG-RGD dendrimer (10 mg, 0.000144 mmol) was dissolved in 5 mL 
DMSO. Then, TEA (7.27 mg, 0.07 mmol) and acetic anhydride (5.87 mg, 0.06 mmol) 
in 5 mL DMSO were slowly added into the dendrimer solution. This reaction was 
stirred at room temperature for 24 h. Afterwards, dialysis and lyophilization were 
followed to get clean/pure G5.NHAc-FI-PEG-RGD. 
 
2.3 Characterization of G5.NHAc-FI-PEG-RGD 
 
1H NMR spectra of the starting materials (NH2-PEG-COOH, MHS, RGD and the 
G5 PAMAM dendrimer), all the intermediate products and the final 
G5.NHAc-FI-PEG-RGD product were recorded using a Bruker Avance II+ 400MHz 
NMR spectrometer. Samples were dissolved in 500-600 µL D2O before 
measurements. UV-Vis spectra were performed using a Lambda 2 UV/Vis 
spectrometer (Perkin-Elmer). Samples were dissolved in 1 mL distilled water before 
measurements. Zeta-potential measurements were performed to measure the potential 
of modified dendrimers at three pH values (5.0, 7.0, and 10.0) using a Zetasizer Nano 
ZS system (Malvern) with a 633nm incident laser beam and a detection angle of 17°. 
Zeta potentials were calculated using the Smoluchowsky model for aqueous 
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suspensions. 
 
2.4 Encapsulation of DOX within G5.NHAc-FI-PEG-RGD dendrimers 
 
G5.NHAc-FI-PEG-RGD dendrimers (10 mg) were dissolved in 1.5 mL water. 
DOX hydrochloride (DOX·HCl) with 10 molar equivalents of dendrimers was 
dissolved in 300 µL methanol followed by adding 5 µL TEA to generate 
non-protonated DOX. Then the dendrimer aqueous solution was mixed with the 
non-protonated DOX solution for 12 hours, allowing the evaporation of the methanol 
solvent. After that, the mixture solution was centrifuged (5423 g for 10 min) in order 
to remove the precipitates, which were due to non-complexed free DOX. The 
supernatant was lyophilized to obtain the G5.NHAc-FI-PEG-RGD/DOX complex. 
The precipitate was saved and re-dissolved into 10 mL methanol for indirect 
determination of the encapsulated amount of DOX by UV-Vis analysis (Lambda 2 
UV/Vis spectrometer, Perkin-Elmer).  
 
2.5 In vitro drug release kinetic studies  
 
A volume of either 2 mL pH = 7.4 PBS buffer or pH = 5 acetate buffer was used 
to dissolve the G5.NHAc-FI-PEG-RGD/DOX complex. 2 ml ethanol was used to 
dissolve free non-protonated DOX. Then, these three solutions were placed in dialysis 
bags with a MWCO of 12,000, and after well-sealed, the bags were immersed in 6 mL 
of pH = 7.4 PBS buffer, pH = 5 acetate buffer, and pH = 7.4 PBS buffer respectively. 
All the systems were kept at 37 °C. At specific time points, 1 mL of the buffer 
medium was taken out for analysis and the volume replenished with the 
corresponding buffer solution. UV-Vis spectroscopy was used to determine the DOX 
content in the removed aliquots.   
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2.6 Host-guest interactions of the dendrimer/DOX complex studies 
    
    One- and two-dimensional (NOESY, DOSY) NMR experiments were carried out 
using a Bruker DRX Avance I 400 MHz NMR spectrometer at the University of 
Debrecen (Hungary). In the case of the G5.NHAc-FI-PEG-RGD/DOX complex at pH 
= 5, 4 mg of G5.NHAc-FI-PEG-RGD dendrimer and 2.5 mg of DOX·HCl were 
co-dissolved within 500 µL of D2O, then 2 µL TEA and 200 µL DCl were used to 
adjust pH ≈ 5.0. In the case of the G5.NHAc-FI-PEG-RGD/DOX complex at pH = 
7.0, 4 mg of dendrimer, 2.5 mg of DOX·HCl and 0.1 µL of TEA were dissolved in 
D2O. 2D-NOESY experiments were obtained with a mixing time of 200 ms and a 
relaxation delay of 1.7 s. Data were processed with cos2 window function in both f1 
and f2 dimensions according to the Bruker protocols. Each of the NOESY spectral 
data was processed with Mestre Nova software. DOSY experiments were performed 
with the following parameters: diffusion time (Δ) = 50 ms, gradient pulse (δ) = 3 ms, 
and relaxation delay = 5 s. DOSY spectral data were processed in 1D and 2D modes 
with Mestre Nova software. 
 
2.7 Cell biological evaluation  
 
U87-MG cells (a human primary glioblastoma cell line in which the αvβ3 
integrin receptors are overexpressed) were continuously grown in the cell culture 
dishes with Eagle's Minimum Essential Medium (EMEM) supplemented with 10% 
fetal bovine serum (FBS), 1% (v/v) of antibiotic and antimycotic 100x solution (AA), 
1% (v/v) of Non essential amino acids 100x (NEAA), 1% (v/v) of Sodium pyruvate 
100x (SP) and 1% (v/v) of L-Glutamine (Glut) 100x. All the reagents mentioned here 
were purchased from Gibco. The culture was maintained at 37 °C in a wet incubator 
with 5 % CO2, and the medium was replaced every 3 days. 
    To check if the G5.NHAc-FI-PEG-RGD/DOX complex was therapeutically 
active, one day before experiments, cells were plated into 96-well plates at a density 
of 1 × 104 cells per well in the EMEM complete medium. The next day, the medium 
CHAPTER 2− MATERIALS AND METHODS 
 
	   25 
was replaced with fresh EMEM complete medium containing free DOX·HCl (5 µM) 
or G5.NHAc-FI-PEG-RGD/DOX complex at the same DOX concentration in PBS 
buffer (10 µL) and then the cells were incubated for 48 h at 37 °C. After treatment 
with DOX or dendrimer/DOX complexes, cell morphology was observed by optical 
microscopy (Nikon Eclipse TE 2000E inverted microscope). The magnification was 
set at 100× for all samples. After morphology observations, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
performed to quantify the viability of the cells. Note that for the DOX encapsulation 
and release studies, water-insoluble DOX was used, while for cell biological 
evaluation, water-soluble DOX·HCl was used as a control to check the therapeutic 
activity of the free drug.  
    To investigate if the uptake of G5.NHAc-FI-PEG-RGD/DOX was 
receptor-mediated, one group of the U87-MG cells was pre-treated with 100 µL of 
RGD solution (2 µM in serum free medium) to block the αvβ3 integrins. Meanwhile, 
the other groups were treated with serum free medium. After 1 h, all the media was 
replaced with fresh complete medium (90 µL), and the G5.NHAc-FI-PEG-RGD/DOX 
complex with DOX concentration of 5 µM in PBS buffer (10 µL) was added to the 
cells and incubated for 4 h. Afterwards, all the media in the wells containing 
dendrimer/DOX complexes were totally taken out and replenished with the same 
volume of fresh complete medium. The cells were then incubated for 48 h at 37°C 
before performing the MTT assay. In parallel cell samples, after 4 h incubation with 
the G5.NHAc-FI-PEG-RGD /DOX complex, the culture medium was removed, and 
the cell nuclei were stained with 2.5 mg/mL 4’,6-diamidino-2-phenylindole (DAPI) at 
room temperature for 35 min and fixed with 3.7 % formaldehyde for 20 min. After, 
the cells were rinsed three times with PBS and three times with ultrapure water. The 
intracellular uptake of free DOX·HCl or G5.NHAc-FI-PEG-RGD/DOX complexes 
was observed by fluorescence microscopy (Nikon Eclipse TE 2000E inverted 
microscope).  
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The MTT assay was used to quantify cell viability. The metabolically active cells 
were detected by adding a 200 µL volume of MTT (5 mg/mL in EMEM medium) to 
each well. After 3 h incubation, the MTT solution in each well was replaced with 200 
µL of DMSO to dissolve the formazan crystals. Then, the plates were read at 550 nm 
using a microplate reader (model Victor3TM 1420, PerkinElmer). The mean and the 
standard deviation were reported (4 replicas were done).  
 
2.8 Statistical analysis 
 
    One way ANOVA statistical analysis was performed to evaluate the significance 
of the experimental data. 0.05 was selected as the significance level, and the data was 
indicated with (*) for p < 0.05, (**) for p < 0.01, and (***) for p < 0.001, 
respectively. 
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                          CHAPTER 3 – RESULTS AND DISCUSSION   
 
3.1 Synthesis and characterization of G5.NHAc-FI-PEG-RGD 
 
G5 PAMAM dendrimers were selected for the synthesis of multifunctional drug 
carriers due to their relative small size, comparable to hemoglobin (5.4 nm), and 
numerous terminal amine groups for multiple conjugation reactions (87, 88). The FI 
moieties covalently attached to the dendrimer surface were used to detect by 
fluorescence the intracellular uptake of the dendrimer carriers. The RGD peptide was 
attached onto the dendrimer surfaces so as to target for the cancer cells that 
overexpress integrin αvβ3 (89). The final acetylation is a key step to improve the 
biocompatibility of the dendrimers and to minimize their non-specific binding to cell 
membranes.  
 
 
Figure. 14 – Synthesis of HOOC-PEG-RGD. 
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Figure 15 – 1H NMR spectrum of HOOC-PEG-RGD in D2O (with integration and 
identifications of peaks).  
The overall synthesis process is depicted in Figure 13. So, the first step was to 
synthesize HOOC-PEG-RGD from HOOC-PEG-NH2 and a cyclic RGD peptide 
(Figure 14). The 1H NMR spectra of HOOC-PEG-NH2, MHS and RGD are presented 
in ANNEX I (Figure 40, 41 and 42, respectively). In the 1H NMR spectrum of 
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HOOC-PEG-RGD in D2O (see Figure 15), we can see the characteristic peak of the 
PEG methylene protons (-OCH2CH2, δ=3.7 ppm) and the characteristic peaks of RGD 
around 7.3-7.4 ppm. Since during dialysis, free RGD was cleared out from the 
reaction mixture, we suppose that the RGD peaks in the 1H NMR spectrum of 
HOOC-PEG-RGD represent only the RGD molecules that were linked to the PEG 
molecules. However, the PEG peaks presented in the spectrum correspond to both 
free and linked PEG. Thus, based on the integration of the relevant peaks, we 
calculated that 0.3 RGD moieties were linked to each PEG.  
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Figure 16 – 1H NMR spectrum of PAMAM G5.NH2-FI dendrimer in D2O. 
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    In a second step, the PAMAM G5.NH2-FI dendrimer was synthesized and 
characterized. The 1H NMR spectrum of the G5 PAMAM dendrimer is presented in 
ANNEX I (Figure 43). The characteristic peak at 3.75 ppm (Ha') in the 1H NMR 
spectrum, corresponding to the aliphatic protons of CH2NHC=S, confirmed the 
formation of a thiourea linkage between the G5 PAMAM dendrimer and the FI 
moeity (see Figure 16). The comparison between aromatic proton peaks at 6.5 ppm 
(1,2,5) and at 7.1 ppm (3,4,6) of FI and the methylene groups of the G5 PAMAM 
dendrimer (Ha) suggest that 10 FI moieties were conjugated to each dendrimer. 
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Figure 17 – 1H NMR spectrum of G5.NH2-FI-PEG-RGD in D2O. 
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Finally, HOOC-PEG-RGD was reacted with PAMAM G5.NH2-FI to give the 
G5.NH2-FI-PEG-RGD product. Following the identification of the characteristic 
peaks of PEG, the G5 PAMAM dendrimer and FI, and after integration, it was found 
that 12 PEG and 4 RGD moieties were attached to each dendrimer molecule. 
According to the literature, 2-3 RGD peptides per dendrimer are sufficient for 
effective targeting (82).   
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   Figure 18 – 1H NMR spectrum of G5.NHAc-FI-PEG-RGD in D2O.  
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Figure 18 shows the 1H NMR spectrum and peak assignment of the final 
G5.NHAc-FI-PEG-RGD conjugate obtained after acetylation of the previous 
compound. The characteristic proton peaks at 3.6 ppm that correspond to PEG can be 
clearly seen. Furthermore, there are overlapping signals in the aromatic region from 
both the FI and the phenyl ring of the peptide apart from the overlapping expected 
from the aliphatic signals of the dendrimer and some aliphatic signals from the 
peptide. After the final acetylation step, the appearance of a new peak at 1.87 ppm 
was detected which was assigned to the -CH3 protons of the acetyl group, indicating 
the complete conversion of the remaining terminal amines to acetamides,	   in 
agreement with previous literature (1).  
UV-Vis spectroscopy was further used to characterize the synthesized 
G5NHAc-FI-PEG-RGD dendrimer conjugates (Figure 19). For comparison, UV-Vis 
spectra of HOOC-PEG-RGD, G5.NH2-FI, and G5.NH2-FI-PEG-RGD were also 
included. HOOC-PEG-RGD shows a characteristic peak for the conjugated peptide at 
λmax = 275 nm, which is in accordance with the data from the literature (82). 
G5.NH2-FI displays a characteristic peak at 500 nm due to the conjugated FI moieties. 
The G5.NH2-FI-PEG-RGD and the G5.NHAc-FI-PEG-RGD conjugates both 
exhibited the featured absorption of FI (500 nm), indicating the success of FI 
conjugation. 
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Figure 19 – UV-Vis spectra of HOOC-PEG-RGD, G5.NH2-FI, G5.NH2-FI-PEG-RGD 
and G5.NHAc-FI-PEG-RGD. 
 
3.2 Encapsulation of DOX within the G5.NHAc-FI-PEG-RGD dendrimers   
 
The neutralization of DOX·HCl to form DOX enables efficient encapsulation of 
the drug within the relatively hydrophobic interior of the dendrimers. Since free DOX 
has low solubility, the formed dendrimer/DOX complexes are expected to have 
improved water-solubility and thus enhanced bioavailability. The formed 
G5.NHAc-FI-PEG-RGD/DOX complexes were characterized by UV-Vis 
spectroscopy (Figure 20). The UV-Vis spectra of DOX dissolved in ethanol and 
G5.NHAc-FI-PEG-RGD dendrimers without DOX were also recorded for comparison. 
It is clear that DOX shows a strong absorption peak at 481 nm. After DOX 
encapsulation, the G5.NHAc-FI-PEG-RGD/DOX complexes have an absorption 
enhancement at 481 nm when compared with the G5.NHAc-FI-PEG-RGD 
dendrimers without DOX under a similar dendrimer concentration. This indicates that 
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DOX has been successfully encapsulated within the G5.NHAc-FI-PEG-RGD 
dendrimers.  
 
	  
Figure 20 –  UV-Vis spectra of free DOX dissolved in ethanol, G5.NHAc-FI- 
PEG-RGD dendrimers dissolved in water, and G5.NHAc-FI-PEG-RGD/DOX 
complexes dissolved in water. 
 
3.2.1 STUDY OF THE PAYLOAD OF DOX PER DENDRIMER 
The payload of DOX encapsulated within the G5.NHAc-FI-PEG-RGD 
dendrimers was obtained by measurement of the non complexed free DOX in solution 
that was recovered by centrifugation, redissolved and analyzed by UV-Vis 
spectroscopy. 
 
 
 
 
 
 
CHAPTER 3 – RESULTS AND DISCUSSION 
	   37 
 
3.2.1.1. Standard curve of DOX in pH = 7.4 PBS buffer. 
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Figure 21 – UV-Vis spectra of DOX in pH = 7.4 PBS buffer. 
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Figure 22 – Standard curve of DOX in pH = 7.4 PBS buffer. 
    A 5 µL volume of TEA was mixed with pH = 7.4 PBS buffer. DOX·HCl was 
then dissolved in this buffer in order to get 0.005, 0.01, 0.02, 0.03, 0.04 and 0.05 
mg/mL DOX solutions. Using UV-Vis absorbance, λmax = 510 nm was recorded for 
DOX in PBS at pH = 7.4 (see Figure 21). The standard curve of DOX in PBS at pH = 
7.4 was then constructed (see Figure 22; y = 15.642x and R2 = 0.99558).   
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3.2.1.2. Standard curve of DOX in pH = 5 acetate buffer. 
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Figure 23 – UV-Vis spectra of DOX in pH = 5 acetate buffer. 
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Figure 24 – Standard curve of DOX in pH = 5 acetate buffer. 
The method described in Section 3.2.1.1 was used to make the standard curve of 
DOX in acetate buffer at pH = 5. From Figure 23 it is clear that λmax = 481 nm for 
DOX in acetate buffer at pH = 5. From the standard curve of DOX in acetate buffer at 
pH = 5 illustrated in Figure 24, y = 29.183x and R2 = 0.99787. 
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3.2.1.3. Standard curve of DOX in methanol.  
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Figure 25 – UV-Vis spectra of DOX in methanol. 
y = 27.062x 
R² = 0.99855
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0 0.01 0.02 0.03 0.04 
A
bs
or
ba
nc
e
Concentration of DOX (mg/ml)
 
Figure 26 – Standard curve of DOX in methanol. 
Again, the same method as that described in Section 3.2.1.1 was used to 
construct the standard curve of DOX in methanol. From the UV-Vis spectra shown in 
Figure 25, λmax = 479 nm for DOX in methanol. From the standard curve of DOX in 
methanol shown in Figure 26, y = 27.062x and R2 = 0.99855. 
 
3.2.1.4. Indirect calculations of the payload of DOX into the dendrimers.   
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Figure 27 – UV-Vis spectrum of free DOX in the precipitate. 
    Note that the experiment investigating the encapsulation of DOX into the 
dendrimers was repeated 3 times. While we only show the results for one experiment 
here, the calculations for determining (i) the number of DOX molecules inside the 
dendrimer, (ii) the encapsulation efficiency, and (iii) the drug loading efficiency were 
based on the results of the three experiments. 
    In the synthesis procedure, G5.NHAc-FI-PEG-RGD dendrimers (11.65 mg) and 
DOX·HCl (0.838 mg) were used. After centrifugation (5423 g for 10 min), the 
precipitate (free DOX) was collected and dissolved into 10 mL methanol for UV-Vis 
analysis. Since the concentration of DOX was still too high to be analyzed by UV-Vis, 
0.2 mL of the DOX solution was mixed with 0.8 mL methanol. The absorbance of 
DOX was then measured to be 0.14187 (see Figure 27). According to the standard 
curve of DOX in methanol, the mass of DOX precipitated was 0.263 mg. Therefore, 
the loaded DOX was 0.585 mg. Based on equations (1) and (2) presented below, the 
encapsulation efficiency (%) and drug loading efficiency (%) results were determined 
(see Table 1). 
Encapsulation efficiency (%) = 100 x m drug in nanoparticles / m total drug      (1) 
Drug loading efficiency (%) = 100 x m drug in nanoparticles / m nanoparticles      (2) 
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Table 1 – Payload of DOX per G5.NHAc-FI-PEG-RGD denrimer. 
Material 
Number of DOX 
inside one 
dendrimer 
Encapsulation 
efficiency (%) 
Drug loading 
efficiency (%) 
G5.NHAc-FI-PEG-RGD 6 69±4 5±3 
     
    Approximately six DOX molecules were found to be complexed with each 
G5.NHAc-FI-PEG-RGD dendrimer, a larger number than that reported for acetylated 
G5 dendrimers modified with FA and FI in a previous work (1). According to the 
explanation in the literature (90), this may be because the hydrophilic PEG chains 
induce less steric hindrance than that induced by the relatively hydrophobic moieties 
of either FI or FA attached onto the dendrimer surface. The encapsulation efficiency 
was 69±4% and the drug loading efficiency was 5±3%. 	  
3.2.2 STUDY OF THE STABILITY AND ZETA POTENTIAL OF THE 
DENDRIMER/DOX COMPLEX 
The stability of the G5.NHAc-FI-PEG-RGD/DOX complexes is very important 
for their biological applications. As can be seen in Figure 28, the lyophilized powders 
of the G5.NHAc-FI-PEG-RGD dendrimers without DOX and the 
G5.NHAc-FI-PEG-RGD/DOX complexes could be dissolved in aqueous solution. As 
expected, the G5.NHAc-FI-PEG-RGD dendrimer solutions present different colors 
relative to the corresponding G5.NHAc-FI-PEG-RGD/DOX complexes. This 
difference in color is due to the presence of DOX in the 
G5.NHAc-FI-PEG-RGD/DOX complexes. This phenomenon suggests that the 
G5.NHAc-FI-PEG-RGD/DOX complexes have similar colloidal stability to that of 
the G5.NHAc-FI-PEG-RGD dendrimers without the drug under the selected pH 
conditions. In addition, their aqueous solutions showed no precipitate for at least two 
months at room temperature under the different pH conditions (pH = 5.0, 7.0, and 
10.0).   
The zeta potentials of the G5.NHAc-FI-PEG-RGD dendrimers and the 
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G5.NHAc-FI-PEG-RGD/DOX complexes at the different pH conditions are listed in 
Table 2. This information is important to understand the cellular interactions of the 
complexes. The smaller values at pH = 7.0 for both dendrimers and complexes 
compared to those at pH = 5.0 indicates that a portion of the dendrimer tertiary 
amines were protonated at pH = 5.0 (91). The change of the surface potential of both 
the dendrimers and complexes with pH followed the same trend as that of 
G5.NHAc-PEG-RGD dendrimers described in a previous work (20). 
pH5.0 pH0 pH0.0 pH5.0 pH.0 pH0.0
(a) (b)
 
Figure 28 – Photographs of the aqueous solutions of G5.NHAc-FI-PEG-RGD 
dendrimers (a) and G5.NHAc-FI-PEG-RGD/DOX complexes (b) under different pH 
conditions. 
    
Table 2 – Zeta potential values of G5.NHAc-FI-PEG-RGD dendrimers and 
G5.NHAc-FI-PEG-RGD/DOX complexes under different pH conditions. 
Materials 
Surface potential 
pH = 5.0 pH = 7.0 pH = 10.0 
G5.NHAc-FI-PEG-RGD Dendrimers 24.6 ± 1.7 1.7 ± 0.2 −33.2 ± 0.7 
G5.NHAc-FI-PEG-RGD/DOX complex 20.4 ± 0.6 0 ± 0.1 −26.8 ± 1.0 
 
3.3 In vitro release kinetic studies 
 
The in vitro release study of DOX from the G5.NHAc-FI-PEG-RGD/DOX 
complexes was performed in either PBS buffer (pH = 7.4) or acetate buffer (pH = 5.0) 
media at 37 °C. In each case, the cumulative release of DOX from the complexes 
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showed that the drug was released in a sustained manner. Moreover, the release of 
DOX from the G5.NHAc-FI-PEG-RGD/DOX complexes followed a biphasic pattern 
that was characterized by an initial fast release followed by a sustained release profile 
(Figure 29). In contrast, the free DOX dissolved in ethanol was quickly released from 
the dialysis bag into the outer PBS buffer phase. In fact, about 80 % free DOX was 
released within just 2 h. In the case of G5.NHAc-FI-PEG-RGD/DOX in acetate buffer 
(pH = 5), about 10 % of the drug was released from the complex within 1 h, and about 
21 % of the DOX was released within 24 h. In comparison, the drug release rate was 
observed to increase for the G5.NHAc-FI-PEG-RGD/DOX complex in PBS buffer 
pH 7.4), with about 35 % of the DOX being released within 1 h and approximately 
57 % of the drug being released within 24 h. The prolonged release profile of DOX 
from the complexes under the two different buffer conditions implies that the 
dendrimer molecules are extremely useful for effective encapsulation and retention of 
the DOX drug. The release rate of DOX from the complexes at pH = 7.4 was higher 
than that at pH = 5.0. This could be due to the fact that under acidic pH conditions, 
the protonated DOX molecules are unlikely able to form strong hydrogen bonding 
with the dendrimer terminal functional groups (nonprotonated amines and terminal 
polar C-O-C bonds of the PEG moieties), leading to a slower release of DOX. In 
contrast, under slightly basic conditions at pH 7.4, the DOX molecules are able to 
form strong hydrogen bonding with the dendrimer terminal functional groups, 
resulting in a faster release rate of the drug from the dendrimer interior. 
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Figure 29 – Cumulative release of DOX from G5.NHAc-FI-PEG-RGD/DOX 
complexes in PBS buffer (pH = 7.4) and acetate buffer (pH = 5.0) at 37 °C. The free 
DOX was dissolved in ethanol against PBS buffer (pH = 7.4) as a control. The data is 
expressed as mean = S.D. (n = 3). 
 
3.4 Host-guest interactions in the G5.NHAc-FI-PEG-RGD/DOX complex 
 
3.4.1 1H NMR SPECTROSCOPY OF THE G5.NHAc-FI-PEG-RGD/DOX 
COMPLEX 
  
To better understand the in vitro drug release results, and the influence of 
dendrimer terminal groups on the properties of dendrimer-based drug delivery 
systems, NMR techniques have been used to investigate the interaction between drug 
molecules and dendrimers (85). 
     1H NMR experiments were performed to evaluate the influence of the pH on the 
interaction between the G5.NHAc-FI-PEG-RGD dendrimer and DOX·HCl in D2O 
(Figure 30). Compared with the 1H NMR of G5.NHAc-FI-PEG-RGD/DOX at pH = 7 
(Figure 30b), an increase in the chemical shift in the peaks (c, e) was detected in the 
spectrum of G5.NHAc-FI-PEG-RGD/DOX at pH = 5 (Figure 30a). This is because 
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above pH = 7, all the tertiary amino groups in the PAMAM dendrimer are 
non-protonated, while below pH = 5, about 70 % of the tertiary amino groups are 
protonated (92). 
The protonation of the tertiary amino groups results in an increase in the chemical 
shift of the adjacent CH2 groups in the PAMAM dendrimers. Moreover, compared 
with the 1H NMR spectrum of DOX·HCl (Figure 30c), the peaks corresponding to the 
DOX protons show obvious changes after mixing with the G5.NHAc-FI-PEG-RGD 
dendrimer under both acid and neutral conditions, thereby revealing that 
intermolecular interactions occur between the dendrimers and the guest molecules. In 
addition, at pH = 5, line broadening of the DOX proton signals is observed. This can 
be attributed to a decrease in the degree of freedom of the drug molecules, and also an 
increase in the ratio of coordinated DOX within the G5.NHAc-FI-PEG-RGD 
dendrimer.  
Figure 30 – 1H NMR spectra of G5.NHAc-FI-PEG-RGD/DOX at pH = 5.0 (a), pH = 
7.0 (b), and the free DOX·HCl with self-pH (c). All samples were dissolved in D2O. 
The DOX concentration in each prepared sample is 5 mg/mL. 
(a)
(b)
(c)
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3.4.2 2D NMR SPECTROSCOPY 
 
    In order to locate the specific structural units involved in the interaction between 
G5.NHAc-FI-PEG-RGD and DOX, 2D-NOESY experiments were performed to 
detect the protons that are spatially close to each other. Figures 31 and 32 show the 
NOESY spectra of the G5.NHAc-FI-PEG-RGD/DOX complex at pH = 7 and at pH = 
5, respectively. The positive sign of the cross-peaks means that the protons involved 
form part of a slowly tumbling molecule. The presence of these cross peaks indicates 
that DOX bonds to or is encapsulated within the dendrimer. However, there are no 
cross-peaks between DOX and the methylene protons found within the interior cavity 
of the dendrimer. Both DOX and the dendrimer only have cross-peaks between their 
own protons in the NOESY spectra. Since the phase of the cross-peaks between the 
DOX protons is the same as that of the diagonal peaks, it may be stated that DOX is 
incorporated into the G5.NHAc-FI-PEG-RGD dendrimers. In other words, DOX 
behaves as a part of the macromolecule.  
 In a previous study (86), it was reported that DOX has a reversible interaction 
with the dendrimer such that both free and coordinated DOX can be found in solution. 
Since the exchange of DOX between the dendrimer and the solution is fast, on the 1H 
chemical shift scale, we cannot see separate peaks for DOX that is located within the 
dendrimer interior and for DOX that is found in the bulk solution. Interestingly, in the 
NOESY spectrum, strong cross-peaks between the protons of PEG and DOX are 
evident. These strong cross-peaks are particularly evident in the spectrum of the 
sample at pH = 7, suggesting a close proximity between the DOX-protons and the 
PEG-protons of the multifunctional dendrimer. As such, we can conclude that there is 
stronger hydrogen bonding between PEG (-OCH2CH2) and non-protonated DOX than 
between DOX and the interior protons of the dendrimer.  
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Figure 31 – 1H-1H NOESY spectra of G5.NHAc-FI-PEG-RGD/DOX·HCl/TEA/D2O 
at a pH = 7, with a mixing time of 200 ms. The sample was prepared by dissolving 4 
mg of the G5.NHAc-FI-PEG-RGD dendrimer in 0.5 mL D2O, followed by mixing 
with 2.5 mg DOX·HCl and TEA. 
 
    The interaction between G5.NHAc-FI-PEG-RGD and DOX was further 
investigated by the DOSY technique. DOSY is a NMR-based technique that is able to 
provide information on the average diffusion coefficients of the components involved 
in a multicomponent system. The diffusion coefficient reflects the hydrodynamic size 
and shape of the measured molecule. In this study, the diffusion coefficients of the 
samples under investigation are listed in Table 3. The average diffusion coefficients 
(D) measured for DOX in the presence of the G5.NHAc-FI-PEG-RGD dendrimer at 
pH = 7.0 and at pH = 5.0 were 1.69 × 10−10 m2/s and 1.39 × 10−10 m2/s, respectively. 
These values are much lower than that of free DOX·HCl (DDOX = 1.96 × 10−10 m2/s). 
This means that some of the DOX molecules move together with the 
G5.NHAc-FI-PEG-RGD dendrimers, thereby lowering the average diffusion rate of 
the formed complexes. The average diffusion coefficient of DOX in the 
G5.NHAc-FI-PEG-RGD/DOX system at pH = 5.0 is smaller when compared with 
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that of the G5.NHAc-FI-PEG-RGD/DOX complex prepared at pH = 7.0. 
 
Figure 32 – 1H-1H NOESY spectra of G5.NHAc-FI-PEG-RGD/DOX·HCl/TEA/DCl 
in D2O at a pH = 5.0, with a mixing time of 200 ms. The sample was prepared by 
dissolving 4 mg of the G5.NHAc-FI-PEG-RGD dendrimer in 0.5 mL D2O, followed 
by mixing with 2.5 mg DOX·HCl and 2 µL TEA. A 200µl volume of DCl was used to 
adjust the pH to ~ 5. 
 
This is indicative of a higher number of DOX molecules being complexed with 
the dendrimer under acidic conditions. Combining the results obtained from the 
NOESY and DOSY experiments, we can reasonably deduce that during the 
dendrimer/DOX complex formation, TEA was used to neutralize DOX·HCl, 
converting it into the hydrophobic DOX drug. In this form, DOX is more compatible 
with the hydrophobic interior of the dendrimer. The use of DCl to adjust the pH of the 
aqueous (D2O) solutions from pH = 7.0 to pH = 5.0 induced the protonation of DOX. 
This protonation of DOX results in a weakened hydrogen bonding interaction with the 
PEG moieties that are conjugated to the dendrimer surfaces. Consequently, the 
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movement of DOX from the interior of the dendrimer towards its surface became 
slower. This slow release of DOX from the dendrimer interior under acidic conditions 
can be explained by the stronger dendrimer/DOX interactions and the weaker 
DOX-PEG interactions that exist.  
Table 3 – Diffusion coefficients of samples (× 10−11 m2/s). 
 
G5.NHAc-FI-PEG-RGD/DOX 
complex G5.NHAc-FI-PEG-RGD 
Free 
DOX·HCl 
 Dendrimer DOX 
pH = 5.0 4.2 13.9 3.9 19.6 
pH = 7.0 4.2 16.9 4.2 19.6 
 
3.5 Therapeutic efficacy of DOX encapsulated within G5.NHAc-FI-PEG-RGD 
dendrimers  
     
The therapeutic efficacy of the DOX encapsulated G5.NHAc-FI-PEG-RGD 
dendrimers on U87-MG cells was tested using the MTT viability assay (see Figure 
33). After incubating the cells with the dendrimer/DOX complexes for 48 h, both free 
DOX·HCl (5 µM) and G5.NHAc-FI-PEG-RGD/DOX complexes prepared using a 
DOX concentration of 5 µM were observed to cause a significant loss in cell viability 
when compared with the control cells that were treated with PBS only (p < 0.001 for 
each). To exclude the possible inherent toxicity of the dendrimers, the multifunctional 
DOX-free G5.NHAc-FI-PEG-RGD dendrimers were prepared using an equivalent 
dendrimer concentration and were then tested on the U87-MG cells. It is clear that the 
G5.NHAc-FI-PEG-RGD dendrimers are non-toxic (p > 0.05). These results indicate 
that the therapeutic activity of the G5.NHAc-FI-PEG-RGD/DOX complexes is solely 
related to the complexed DOX drug. 
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Figure 33 – MTT assay of the viability of the U87-MG cells after treatment with 10 
µL PBS buffer (control), free DOX·HCl dissolved in 10 µL PBS (5 µM), 
G5.NHAc-FI- PEG-RGD/DOX complexes with a DOX concentration of 5 µM, and 
DOX-free G5.NHAc-FI-PEG-RGD dendrimers prepared using the same dendrimer 
concentration. The data is expressed as mean ± S.D. (n = 4). Statistical analysis was 
performed to compare the cell viability upon treatment with PBS, (***) for p < 0.001. 
(a) (b) (c)
(d) (e)
 
Figure 34 – Photomicrographs of the control U87-MG cells without treatment (a) and 
the U87-MG cells treated with 10 µL PBS (b), free DOX·HCl (5 µM) (c), DOX (5 
µM) complexed with G5.NHAc-FI-PEG-RGD dendrimers (d), and DOX-free 
G5.NHAc-FI-PEG-RGD	   dendrimers prepared using the same dendrimer 
concentration as that used when preparing the G5.NHAc-FI-PEG-RGD/DOX 
complexes (e). 
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The cytotoxic effect of the G5.NHAc-FI-PEG-RGD/DOX complexes was further 
confirmed by the microscopic visualization of the morphology of the U87-MG cells 
after treatment with the complexes. Figure 34 shows the morphology of the untreated 
U87-MG cells, as well as the morphology of the cells treated with either PBS buffer, 
free DOX·HCl, or the G5.NHAc-FI-PEG-RGD/DOX complexes. The U87-MG cells 
treated either with DOX·HCl in PBS (Figure 34c) or with the 
G5.NHAc-FI-PEG-RGD/DOX complexes prepared using a similar DOX 
concentration (Figure 34d) induced comparable morphological changes. Here, a 
significant portion of the cells became rounded and non-adherent, indicative of cell 
death. In contrast, no rounded and detached cells were visualized in the control cells 
that did not undergo DOX treatment (Figure 34a) and in the cells that were treated 
with only 10 µL PBS (Figure 34b). A similar observation was made for the U87-MG 
cells that were treated with the DOX-free G5.NHAc-FI-PEG-RGD dendrimers that 
were prepared using the same dendrimer concentration as that used when preparing 
the G5.NHAc-FI-PEG-RGD/DOX complexes. It was also found that the 
multifunctional G5.NHAc-FI-PEG-RGD dendrimers did not induce any prominent 
morphological modifications in the cells (Figure 34e). This data further suggests that 
the anticancer activity of the G5.NHAc-FI-PEG-RGD/DOX complexes is solely 
related to the complexed DOX drug, thereby corroborating the MTT assay results. 
 
3.6 Targeted ability of G5.NHAc-FI-PEG-RGD complexes 
    
    The cyclic RGD peptide was selected as a targeting ligand to be conjugated onto 
the dendrimer surface so as to achieve the specific delivery of DOX to cancer cells 
overexpressing αvβ3 integrins on their membrane surface. The high affinity of αvβ3 
integrins for RGD peptides is expected to allow the specific binding and 
internalization of the RGD-modified dendrimers into cancer cells through 
receptor-mediated endocytosis. U87-MG cells were selected for the specific binding 
and treatment with the G5.NHAc-FI-PEG-RGD/DOX complexes as these cells 
overexpress integrins on their membrane surface. 
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3.6.1 DETERMINATION OF RGD CONCENTRATION FOR BLOCKING 
INTEGRIN αvβ3 
 
In order to test the targeting ability of G5.NHAc-FI-PEG-RGD/DOX, it is 
important to set up a control group of U87-MG cells in which the αvβ3 integrins are 
inactive. This means that the αvβ3 integrins that exist on the U87-MG cell surface 
must be totally pre-blocked with free RGD peptides before performing the cell 
internalization experiments. 
U87-MG cells were incubated for 1 h at 37 °C with 0.0, 0.5, 1, 2 and 4 µM cyclic 
RGD. At this stage, G5.NHAc-FI-PEG-RGD dendrimers complexed with 5 µM DOX 
were added to the pre-treated U87-MG cells for another 4 h at 37 °C. The MTT assay 
showed cell viability values of 69.7±6.4, 92.2±5.4, 95.8±5.5, 96.5±5.1 and 
90.5±2.7 % for the U87-MG cells pre-treated with 0.0, 0.5, 1, 2 and 4 µM cyclic RGD, 
respectively (see Figure 35).  Thus the internalization of the 
G5.NHAc-FI-PEG-RGD/DOX complexes by the U87-MG cells was, to a 
considerable extent, effectively inhibited as a result of the αvβ3 integrins on the cell 
surface being blocked by cyclic RGD. It is important to note that, according to the 
literature, the use of a 2 µM RGD concentration and a 1 h incubation period is 
sufficient to block the U87-MG cell surface αvβ3 integrins (93). However, in the 
present study it was found that complete integrin blocking was achieved when using a 
lower RGD concentration of 0.5 µM. Nevertheless, a 2 µM RGD concentration was 
still used in the following studies to block the αvβ3 integrins located on the U87-MG 
cell surface. 
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Figure 35 – Cell viability of U87-MG cells pre-treated with 0, 0.5, 1, 2, 4 µM RGD 
for 1 h and then finally treated with G5.NHAc-FI-PEG-RGD dendrimers complexed 
with 5 µM DOX. The data is expressed as mean ± S.D. (n = 4). Statistical analysis 
was performed to compare the cell viability upon treatment with 0 µM RGD, (*) for p 
< 0.05. 
 
3.6.2 CELL UPTAKE OF G5.NHAc-FI-PEG-RGD/DOX 
 
To evaluate the targeting specificity and uptake of the multifunctional 
RGD-modified G5 dendrimers, comparisons were made between the non-blocked 
U87-MG cells and the U87-MG cells pre-treated with a 2 µM RGD solution.     
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Figure 36 – Fluorescence microscopy images of U87-MG cells treated with EMEM 
medium A), PBS B), the G5.NHAc-FI-PEG-RGD/DOX complexes only C), and 2 
µM RGD for 1 h followed by the G5.NHAc-FI-PEG-RGD/DOX complexes for 4 h 
D). In all cases, the DOX concentration was kept at 5 µM. For each panel, the images 
from left to right show the bright field, the blue fluorescence channel detecting the 
DAPI dye, the red fluorescence channel detecting DOX, the green fluorescence 
channel detecting the FI, and the merged images of the above three modes. All the 
images were collected under the equivalent instrumental conditions. 
 
The conjugation of the FI moiety onto the G5 dendrimers enables the 
fluorescence microscopic imaging of the cellular uptake of the 
G5.NHAc-FI-PEG-RGD/DOX complexes into the U87-MG cells. Figure 36 shows 
that after 4 h incubation of the U87-MG cells with the G5.NHAc-FI-PEG-RGD/DOX 
complexes, only the cells that did not undergo pre-blocking with free RGD showed 
significant red and green fluorescence signals. These signals are associated with the 
specific internalization of the G5.NHAc-FI-PEG-RGD/DOX complexes into the 
cytoplasm of the cells (Figure 36 (C3-4)). The green (Figure 36 (C4)) and the red 
(Figure 36 (C3)) fluorescence signals are indicative that both the FI-labeled dendrimer 
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and the complexed DOX were internalized by the U87-MG cells. The slightly purple 
signals evident in the merged images in Figure 36 (C5) further demonstrate this 
phenomenon. In comparison, under similar microscopic conditions, the U87-MG cells 
that were pre-blocked with free RGD and that were treated with the same complexes 
showed less intense red and green fluorescence signals (Figure 36 (D3-4)). Overall, 
the results combined suggest that the G5.NHAc-FI-PEG-RGD dendrimers display an 
important targeting ability.   
 
3.6.3 MTT ASSAY TO TEST THE TARGETING INHIBITION OF 
G5.NHAc-FI-PEG-RGD/DOX 
 
To prove that the G5.NHAc-FI-PEG-RGD/DOX complexes were able to 
specifically inhibit U87-MG cells, the cells were incubated with the complexes for 4 h. 
The medium in each well was then replaced with the same volume of fresh medium 
and incubated for a further 48 h at 37 °C. At this stage, the MTT assay was performed 
to assess the viability of the cells. Figure 37 shows the viability of the U87-MG cells 
after treatment with 10 µL of either PBS buffer (control), the 
G5.NHAc-FI-PEG-RGD/DOX complex (DOX concentration of 5 µM) without 
integrin pre-blocking or the G5.NHAc-FI-PEG-RGD/DOX complex (DOX 
concentration of 5 µM) with integrin pre-blocking for 1h. Under each condition, the 
cell viability values recorded were 100.0±5.0, 69.7±6.4 and 96.5±5.1 %, respectively. 
It can be seen that the treatment of the U87-MG cells with the 
G5.NHAc-FI-PEG-RGD/DOX complexes resulted in a significant decrease in the cell 
viability (p <0.01 versus control). In contrast, RGD pre-blocking of the U87-MG cells 
led to 96.5% viability. From this experiment it is evident that the 
G5.NHAc-FI-PEG-RGD/DOX complexes provided a targeted inhibition of the cancer 
cells via RGD receptor-mediated binding and intracellular uptake.  
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Figure 37 – MTT viability assay of the U87-MG cells after 4 h treatment with either 
10 µL PBS or with the G5.NHAc-FI-PEG-RGD/DOX complexes (DOX 
concentration of 5 µM) prepared with and without integrin pre-blocking using a 2 µM 
RGD solution for 1 h. After incubating the U87-MG cells with the dendrimer/DOX 
complexes for 48h, the MTT assay was performed. The data is expressed as mean ± 
S.D. (n = 4). Statistical analysis was performed to compare the cell viability upon 
treatment with PBS buffer, (**) for p < 0.01. 
 
3.6.4 DOSAGE OF G5.NHAc-FI-PEG-RGD/DOX & CELL VIABILITY  
 
    In this study, U87-MG cells were first pretreated with serum free EMEM or with 
2 µM RGD for 1h. The U87-MG cells were then incubated for an additional 4 h at 
37°C following the treatment of the cells with G5.NHAc-FI-PEG-RGD/DOX 
complexes prepared taking into account DOX concentrations of 1.25, 2.5, 5, 10 and 
20 µM. The cell viability of the U87-MG cells after treatment with the 
G5.NHAc-FI-PEG-RGD/DOX complexes was 76.8±5.2, 82.7±14.2, 71.9±6.5, 
64.8±9.2, and 57.4±4.2 % for RGD = 0 µM; and 98.8±4.1, 83.7±7.2, 86.3±12.9, 
73.9±6.0 and 67.9±8.5 % for RGD = 2 µM, respectively (see Figure 38). From the 
MTT assay results recorded in Figure 32, it was found that a higher concentration of 
DOX led to lower values of cell viability in the U87-MG cells. 
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Figure 38 – Cell viability of the U87-MG cells treated with 0 µM RGD (black) or 
with 2 µM RGD (red) for 1 h. The cells were then treated for an additional 4 h with 
G5.NHAc-FI-PEG-RGD/DOX complexes prepared taking into account DOX 
concentrations of 1.25, 2.5, 5, 10, 20 µM . The data is expressed as mean ± S.D. (n = 
4). Statistical analysis was performed to compare the cell viability between the 
U87-MG cells that underwent treatment with or without RGD under the same 
concentration of DOX, (***) for p < 0.001. 
 
3.6.5 INCUBATION TIME & CELL VIABILITY 	  
In this study, the G5.NHAc-FI-PEG-RGD dendrimer was complexed with 5 µM 
DOX. The prepared complexes were then placed in contact with the U87-MG cells 
for 0, 1, 2, 4 and 6.5 h in serum-containing medium. The results obtained using the 
MTT assay showed that the viability of the U87-MG cells decreased with longer 
incubation times (see Figure 39).  
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Figure 39 – Cell viability of the U87-MG cells treated with the 
G5.NHAc-FI-PEG-RGD/DOX complexes using different incubation times. 
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CHAPTER 4 – GENERAL CONCLUSIONS 
 
    In summary, multifunctional FI-, PEG-, RGD- modified G5 dendrimers 
(G5.NHAc-FI-PEG-RGD) were synthesized, and successfully loaded with the 
antitumor agent, DOX. The formed G5.NHAc-FI-PEG-RGD/DOX complexes were 
stable and displayed a sustained drug release profile. Importantly, the formed 
G5.NHAc-FI-PEG-RGD/DOX complexes were able to specifically target U87-MG 
cells that overexpress αvβ3 integrins and displayed specific toxicity towards these 
cells. Moreover, the results demonstrated a good correlation between the NMR 
studies (host/guest interactions) and the release profile of the drug. Overall, this study 
provided valuable knowledge for the design of other different multifunctional 
dendrimer-based drug carrier systems that may even be considered beyond anticancer 
applications. 
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ANNEX I – 1H NMR spectra of starting materials 
	  
Figure 40 – 1H NMR of HOOC-PEG-NH2 in D2O 
 
 
 
 
Figure 41 – 1H NMR of MHS in D2O. 
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Figure 42 – 1H NMR of RGD in D2O. 
 
 
Figure 43 – 1H NMR of G5 PAMAM in D2O. 
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